SEA-BCMA

Verified

Overview

SEA-BCMA is a new antibody targeting the BCMA protein and being tested in multiple myeloma. It was made using proprietary Sugar Engineered Antibody (SEA) technology, which adds sugar molecules to the original antibody. The approach is believed to improve the binding of anti-tumor immune cells to the antibody, enhancing the immune response against cancer.

SparkCures ID 288
Developed By Seattle Genetics
Generic Name SEA-BCMA
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Verified
A phase 1 study of SEA-BCMA in patients with relapsed or refractory multiple myeloma
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
View Trial
Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified
A phase 1 study of SEA-BCMA in patients with relapsed or refractory multiple myeloma
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
View Trial
Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.

SparkCures Verified

SparkCures is working closely with Seattle Genetics to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.

Learn more about how we work with industry partners